---
figid: PMC8905338__bnab019f0005
figtitle: Personalized Management of Pheochromocytoma and Paraganglioma
organisms:
- Saccharomyces cerevisiae
- Ficus racemosa
- Homo sapiens
pmcid: PMC8905338
filename: bnab019f0005.jpg
figlink: /pmc/articles/PMC8905338/figure/F5/
number: F5
caption: Gene mutations leading to an activation of kinase signaling pathways (cluster
  2) and derived molecular targets for a personalized therapy. Mutations in RET, NF1,
  HRAS, TMEM127, MAX, FGFR1, Met, MERTK, BRAF and NGFR activate phosphatidylinositol-3-kinase
  (PI3K)/AKT, mammalian target of rapamycin (mTORC1)/p70S6 kinase (p70S6K), and RAS/RAF/ERK
  signaling pathways. Highlighted in red are potential drugs that address the molecular
  changes in cluster 2 PPGLs and are in preclinical and clinical evaluation. Molecular-targeted
  signaling pathway inhibitors (alone and in combination) might be specifically effective
  in these tumors. Moreover, similar to cluster 1, cluster 2 PPGLs provide the somatostatin
  receptor (possibly lower expression compared to cluster 1) and the norepinephrine
  transporter (possibly higher expression compared to cluster 1) as potential targets
  for the treatment of these tumors. Immune checkpoint inhibitors and drugs addressing
  DNA repair and synthesis mechanisms are furthermore under evaluation.
papertitle: Personalized Management of Pheochromocytoma and Paraganglioma.
reftext: Svenja NÃ¶lting, et al. Endocr Rev. 2022 Apr;43(2):199-239.
year: '2022'
doi: 10.1210/endrev/bnab019
journal_title: Endocrine Reviews
journal_nlm_ta: Endocr Rev
publisher_name: Oxford University Press
keywords: pheochromocytoma | paraganglioma | molecular cluster | diagnostics | follow-up
  | treatment
automl_pathway: 0.9462246
figid_alias: PMC8905338__F5
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC8905338__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8905338__bnab019f0005.html
  '@type': Dataset
  description: Gene mutations leading to an activation of kinase signaling pathways
    (cluster 2) and derived molecular targets for a personalized therapy. Mutations
    in RET, NF1, HRAS, TMEM127, MAX, FGFR1, Met, MERTK, BRAF and NGFR activate phosphatidylinositol-3-kinase
    (PI3K)/AKT, mammalian target of rapamycin (mTORC1)/p70S6 kinase (p70S6K), and
    RAS/RAF/ERK signaling pathways. Highlighted in red are potential drugs that address
    the molecular changes in cluster 2 PPGLs and are in preclinical and clinical evaluation.
    Molecular-targeted signaling pathway inhibitors (alone and in combination) might
    be specifically effective in these tumors. Moreover, similar to cluster 1, cluster
    2 PPGLs provide the somatostatin receptor (possibly lower expression compared
    to cluster 1) and the norepinephrine transporter (possibly higher expression compared
    to cluster 1) as potential targets for the treatment of these tumors. Immune checkpoint
    inhibitors and drugs addressing DNA repair and synthesis mechanisms are furthermore
    under evaluation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - EGFR
  - FGFR1
  - MERTK
  - RET
  - KDR
  - FLT1
  - FLT4
  - PDGFRB
  - PDGFRA
  - HIF1A
  - EPAS1
  - HIF3A
  - ARNT
  - ARNT2
  - BMAL1
  - TMEM127
  - EIF4E
  - NF1
  - MAP2K1
  - EPHB2
  - MAPK1
  - MAPK3
  - MYC
  - MAX
  - ADHFE1
  - HDAC1
  - SSTR2
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK4
  - CDK5
  - CDK6
  - CDK7
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK1
  - CDK2
  - PDCD1
  - RPL17
  - SNCA
  - SPATA2
  - RPL17-C18orf32
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
---
